drugset / Trial / NCT00666835
Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia and treated previously with a stable dose of ERYPO® intravenously.
Timeline
- Start
- 2004-04
- Primary completion
- 2006-01
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 300 iu/kg | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | 1000 iu | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | 2000 iu | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | 4000 iu | Intravenous |